Physician profile
Pha Tran
NPI 1447848247
$1,079.05
in general payments reported to CMS, 2019-2025
18 companies · $38.00 in 2025
The $38.00 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $98.27 · 2024: $943 · 2025: $38.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $161.67 | 2024 | Wegovy |
| Astellas Pharma US INC | $125.00 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $116.47 | 2024 | Invega Sustenna, Invega Trinza |
| Sage Therapeutics, LLC | $112.41 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.32 | 2024 | Caplyta |
| Organon LLC | $66.66 | 2023 | Nexplanon |
| Neurocrine Biosciences, INC. | $63.53 | 2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $58.82 | 2024-2025 | Vaxneuvance, Gardasil, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $44.02 | 2024 | Abilify Asimtufii, Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $41.84 | 2024 | |
| Exeltis, USA INC. | $36.77 | 2024 | Slynd |
| Radius Health, INC. | $31.61 | 2023 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $27.86 | 2024 | Uzedy |
| Biogen, INC. | $23.52 | 2024 | Zurzuvae |
| Alkermes, INC. | $21.65 | 2024 | Aristada, Lybalvi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.55 | 2024 | Mounjaro |
| Aspira Women'S Health INC | $20.31 | 2024 | Ova1 |
| Optinose US, INC. | $18.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pha Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.